Etiopatogenesis de la esclerosis sistemica. Revisión de la literatura
Palabras clave:
Esclerosis, célula endotelial, fibroblásto.Resumen
Se realiza una revisión sobre los diferentes factores que están comprometidos en la patogénesis de la Esclerosis Sistémica. Se analizan tres eventos fisiopatogénicos: alteraciones vasculares, respuesta inmune anormal y trastornos en la regulación del metabolismo del tejido conectivo.
Las anormalidades de capilares y arteriolas halladas en numerosos tejidos, sugieren que los cambios vasculares son primarios en la patogénesis, y capaces de inducir fibrosis; a lo anterior se suman linfocinas y monocinas que estimulan o inhiben el movimiento del fibroblásto, la síntesis de colágeno y glicosaminoglicanos.
Finalmente, otra célula comprometida es el mastocito, el cual es estimulado por los IL-3 e IL-4 e induce proliferación de células mesenquimales y activación de la célula endotelial.
Biografía del autor/a
Esperanza Melendez Ramirez, Centro Dermatológico Federico Lleras Acosta
MD, Residente III Dermatología Centro Dermatológico Federico Lleras Acosta
Santafé de Bogota
Angela Susana López Fajardo , Centro Dermatológico Federico Lleras Acosta
MD, Residente II Dermatología Centro Dermatológico Federico Lleras Acosta
Santafé de Bogota
Referencias bibliográficas
LeRoy EC. Black C Fleischmajer R et al. Scleroderma (Systemic Sclerosis): Classification, Subsets and Pathogenesis. Rheumatol 1988; 15(2). 202-205.
Steen VP and Medsger TA. Epidemiology and Natural History of Systemic Sclerosis. Rheum Dis Clin North Am, 1990; 16(1): 1-10.
https://doi.org/10.1016/j.rdc.2007.12.001
Wolff DJ, Needleman BW, Wasserman SS et al. Spontaneous and Clastogen Induced Chromosomal Breakage in Scleroderma. J Rheumatol 1991; 18(6): 837-840.
Fishman SJ, Russo GG. The Toxic Pseudosclerodermas Int J Dermatol 1991; 30(12): 837-842.
https://doi.org/10.1111/j.1365-4362.1991.tb04346.x
Rustin MH, Bull HA. Ziegler V et al. Silica-associated Systemic Sclerosis is Clinically, Serologically, and Immunological indistinguishable from Idiopathic Systemic Sclerosis Bi I Dermat 1990; 123(6): 725-734.
https://doi.org/10.1111/j.1365-2133.1990.tb04189.x
Haustein UF, Herrmann K, Bohme HJ. Pathogenesis of progressive Systemic Sclerosis. Int J Dermatol 1986; 25(5): 286-293.
https://doi.org/10.1111/j.1365-4362.1986.tb02244.x
Carpentier PH. Maricq HR. Microvasculature in Systemic Sclerosis. Rheum Dis Clin North Am. 1990; 16(1): 75-91.
Studer A, Hunziker T, Lutolf O et al. Quantitative Nailfold Capillary Microscopy in Cutaneous and Systemic Lupus Erythematosus and Localized Systemic Scleroderma. J Am Acad Dermatol 1991; 24(6 Pt 1): 941-945.
https://doi.org/10.1016/0190-9622(91)70150-Z
Kallenberg CG, Early Detection of Connective Tissue Disease in Patients with Raynaud's Phenomenon. Rheum Dis Clin North Am 1990; 16(1); 11-30.
Krieg T. Meurer M. Systemic Scleroderma Clinical and Pathophysiologic Aspects, J Am Acad Dermatol 1988018(3): 457-481.
https://doi.org/10.1016/S0190-9622(88)70070-5
Kahaleh MB. Vascular Disease in Scleroderma Endothelial T Lymphocyte-Fibroblast Interactions. Rheum Dis Clin North Am 1990; 1611): 53-73.
Penning C. Cunningham J. French MA et al. Antibody dependent Cellular Ototoxicity of Human Vascular Endothelium in Systemic Sclerosis. Clin Exp Immunol 1984; 53(3):548-556.
Freemont AJ. Hoyland J. Fielding P et al. Studies of the Microvascular endothelium in Uninvolved Skin of Patients with Systemic Sclerosis: Direct Evidence for a Generalized Microangiopatby. Br J Dermatol 1992; 126(6): 561-568.
https://doi.org/10.1111/j.1365-2133.1992.tb00100.x
Gonzalez-Amaro R, Alcocer-Varela J, Alarcón-Segovia D. Natural Killer Cell Activity in the Systemic Connective Tissue Disease. J Rheumatol 1988; 15(8): 1223-1228.
Lima J, Fonollosa V, Fernansez-Cortijo J et al. Platelet Activation, Endothelial Cell Dysfunction in the Absence of Anticardiolipin Antihoides in Systemic Sclerosis. J Rheumatol 1991:18(12): 1833-1836.
Postlethwaite AE. Early Immune Events in Sclerodrma. Rheum Dis Clin North Am 1990; 16(1): 125-131.
Hawrylko E, Spertus A, Mele CA et al. Increased IL-2 Production in Response to Human Type I Collagen Stimulation in Patients with Systemic Sclerosis. Arthritis Rheum 1991; 34(5): 580-587.
https://doi.org/10.1002/art.1780340510
Gruschwitz M, Muller HJ, Sepp N et al. Transcription and Expression of TGF-B in the Skin of Progressive Systemic Sclerosis. A Mediator of Fibrosis? J Invest Dermatol 1990; 94(2): 197-203.
https://doi.org/10.1111/1523-1747.ep12874503
Smith EA. LeRoy EC. A Possible Role for TGF-B in Systemicv Sclerosis. J Invest Dermatol (Suppl) 1990; 95(6): 125s-127s.
https://doi.org/10.1111/1523-1747.ep12874998
Vouri T, Kahari VM, Black C et al. Expression of Osteonectina. Decorin, TGF-B 1 Genes in Fibroblasts Cultured from Patients with Systemic Sclerosis and Morphea. J Rheumatol 1991; 18(2): 247-251.
IVrlish JS, Lemlich G, Fleischmajer R. Identification of Collagen Fibrils in Scleroderma Skin. J Invest. Dermatol 1988; 90(1): 48-5-1.
https://doi.org/10.1111/1523-1747.ep12462561
Veli-Mati K, Sandkerg M. Identification of Fibroblast Response for Increased Collagen Production in Localized Scleroderma by in situ Hybridization. J Invest Dermatol. 199!; 664-670.
Frances C, Branchet MC. Bletry O et al. Skin Collagen horn Scleroderma Patients Before and After Cyclosporin A Treatment. Clin Exp Dermatol 1988; 13(1): 1-3.
https://doi.org/10.1111/j.1365-2230.1988.tb00637.x
Claman HN. Mast Cell Change in a Case of Rapidly Progressive Scleroderma-ultra-structural Analysis. J Invest Dermatol. 1989; 92(2): 290-295.
Cómo citar
Descargas
Descargas
Publicado
Cómo citar
Número
Sección
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
